Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant

Table 1

Patient characteristics.

Characteristic	No. of patients (𝑛=61)	% of total
Age (yrs)
≤65	22	36.1%
>65	39	63.9%
Pretreatment PSA (ng/mL)
<10	50	82.0%
≥10	11	18.0%
Gleason score
6	7	11.5%
7	48	78.7%
8	6	9.8%
Tumor stage
T1c	34	55.7%
T2a	19	31.1%
T2b	6	9.8%
T2c	2	3.3%
Risk group
Low	3	4.9%
Intermediate	52	85.2%
High	6	9.8%
Androgen deprivation therapy
No	50	82.0%
Yes	11	18.0%

PSA: prostate specific antigen.